| Autor: |
Chengzhi Zhou, Yilin Yang, Xinqing Lin, Nianxin Fang, Likun Chen, Juhong Jiang, Haiyi Deng, Yu Deng, Minghui Wan, Guihuan Qiu, Ni Sun, Di Wu, Xiang Long, Changhao Zhong, Xiaohong Xie, Zhanhong Xie, Ming Liu, Ming Ouyang, Yinyin Qin, Francesco Petrella, Alfonso Fiorelli, Sara Bravaccini, Yuki Kataoka, Satoshi Watanabe, Taichiro Goto, Piergiorgio Solli, Hitoshi Igai, Yuichi Saito, Nikolaos Tsoukalas, Takeo Nakada, Shiyue Li, Rongchang Chen |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Immunology, Vol 13 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1664-3224 |
| DOI: |
10.3389/fimmu.2022.935779 |
| Popis: |
BackgroundCheckpoint inhibitor–related pneumonitis (CIP) is a lethal immune-related adverse event. However, the development process of CIP, which may provide insight into more effective management, has not been extensively examined.MethodsWe conducted a multicenter retrospective analysis of 56 patients who developed CIP. Clinical characteristics, radiological features, histologic features, and laboratory tests were analyzed. After a comprehensive analysis, we proposed acute, subacute, and chronic phases of CIP and summarized each phase’s characteristics.ResultsThere were 51 patients in the acute phase, 22 in the subacute phase, and 11 in the chronic phase. The median interval time from the beginning of CIP to the different phases was calculated (acute phase: ≤4.9 weeks; subacute phase: 4.9~13.1 weeks; and chronic phase: ≥13.1 weeks). The symptoms relieved from the acute phase to the chronic phase, and the CIP grade and Performance Status score decreased (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
